Prescribing of Proton Pump Inhibitors for Prevention of Upper Gastrointestinal Bleeding in US Outpatient Visits.

Autor:	Kurlander JE; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; VA Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Electronic address: jkurland@umich.edu., Mafi JN; Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Racz MJ; Department of Life Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York., Barnes GD; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan., Saini SD; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, VA Ann Arbor, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan., Meek PD; Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Sep; Vol. 22 (9), pp. 1937-1941.e4. Date of Electronic Publication: 2024 Feb 15.
DOI:	10.1016/j.cgh.2024.01.047
Abstrakt:	Antisecretory medications, primarily proton pump inhibitors (PPIs), have proven effective in reducing upper gastrointestinal toxicities, including upper gastrointestinal bleeding (UGIB), associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin, which are among the most commonly used medications in the United States. 1 Accordingly, professional guidance recommends PPIs for patients at high risk for UGIB. 2-4 However, little is known about trends in use of antisecretory medications for gastrointestinal prophylaxis ("gastroprotection"). Herein, we examined contemporary use and prescribing of antisecretory medications in visits by patients at high risk for UGIB, relative to visits by patients diagnosed with acid-related disorders. (Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu